Imperial Valley News Center
FDA approves new HIV treatment for patients who have limited treatment options
- Details
- Written by Theresa Eisenman
Washington, DC - The U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.
Monoclonal antibodies crucial to fighting emerging infectious diseases
- Details
- Written by Elizabeth Deatrick
Washington, DC - Monoclonal antibodies (mAbs) - preparations of a specific type of antibody designed to bind to a single target - have shown promise in the fight against cancer and autoimmune diseases. They also may play a critical role in future battles against emerging infectious disease outbreaks, according to a new article by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The article is published online this week by the New England Journal of Medicine and outlines the potential uses for mAbs as treatments for infectious diseases and as a prevention tool for protecting individuals at risk of infection and slowing disease outbreaks.
Antiviral drug not beneficial for reducing mother-to-child transmission of hepatitis B when added to existing preventatives
- Details
- Written by Linda Huynh
Washington, DC - Tenofovir disoproxil fumarate (TDF), an antiviral drug commonly prescribed to treat hepatitis B infection, does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery, according to a phase III clinical trial in Thailand funded by the National Institutes of Health. The study tested TDF therapy in addition to the standard preventative regimen - administration of hepatitis B vaccine and protective antibodies at birth - to explore the drug’s potential effects on mother-to-child transmission rates. The results appear in the New England Journal of Medicine.
One-month tuberculosis prophylaxis as effective as nine-month regimen for people living with HIV
- Details
- Written by Hillary Hoffman
Washington, DC - A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial. Adults and adolescents in the trial were more likely to complete the short-course regimen - consisting of daily doses of the antibiotics rifapentine and isoniazid for four weeks than the standard nine-month regimen of daily isoniazid.
Short-term increases in inhaled steroid doses do not prevent asthma flare-ups in children
- Details
- Written by National Heart, Lung, and Blood Institute
Washington, DC - Researchers have found that temporarily increasing the dosage of inhaled steroids when asthma symptoms begin to worsen does not effectively prevent severe flare-ups, and may be associated with slowing a child’s growth, challenging a common medical practice involving children with mild-to-moderate asthma.
Goal to fusion power on the fast track
- Details
- Written by David Chandler
Cambridge, Massachusetts - Progress toward the long-sought dream of fusion power - potentially an inexhaustible and zero-carbon source of energy - could be about to take a dramatic leap forward.
Page 1522 of 3785